Spots Global Cancer Trial Database for Apatinib as First -Line Treatment for Advanced Esophagus Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Apatinib as First -Line Treatment for Advanced Esophagus Cancer
Official Title: An Exploratory and Open Clinical Study of Apatinib Mesylate as First-line Treatment for Advanced Esophagus Cancer.
Study ID: NCT03542422
Conditions
Interventions
Study Description
Brief Summary: An Exploratory study of Amapinib for patients with advanced esophagus cancer .
Detailed Description: An Exploratory study of Amapinib for patients with advanced esophagus cancer . Eligible are patients with advanced esophagus cancer. Apatinib (500mg) is given daily as follows: Metastasis after primary treatment : Apatinib + yew + platinum. Local recurrence after previous surgery/radiotherapy: Apatinib alone or in combination with platinum-based chemotherapy One therapy cycle has 28 days. Tumor response is evaluated every 2 cycles.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
